IASO Bio Presented the Outcomes of Relapsed/Refractory Multiple Myeloma (R/RMM) Patients with Renal Impairment Treated with Equecabtagene Autoleucel (Fucaso™) at 2024 IMS Annual Meeting

SHANGHAI and NANJING, China and SAN JOSE, Calif., Sept. 27, 2024 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell therapy and antibody products, today announced a poster presentation of the outcomes of relapsed/refractory multiple myeloma (R/RMM) patients with renal impairment (RI) treated with the fully human anti-BCMA CAR-T cell therapy Equecabtagene Autoleucel (Eque-cel, Fucaso^TM), from the pivotal phase 2 FUMANBA-1 study at the 2024 International Myeloma Society (IMS) Annual Meeting. Results indicate that Eque-cel achieve equivalent efficacy and safety for R/RMM patients with renal impairment and improve the renal function as well.

Abstract Number: P-100
Abstract Title: The Outcomes of R/R MM Patients with Renal Impairment (RI) Treated with Eque-cel in the Pivotal Phase 2 FUMANBA-1 Study
Presentation Date: September 26, 2024（UTC-3)

A total of 91 subjects, all without prior CAR-T treatment, were enrolled in the FUMANBA-1 study to receive Eque-cel, with a median follow-up of 18.07 months. Subjects were divided into RI group and non-RI group, based on creatinine clearance (CrCl) levels at the time of CAR-T therapy, of which 28 subjects had RI with CrCl between 40 and 70 ml/min, and 63 belonged to non-RI group, with CrCl>70 ml/min.

The baseline characteristics in the RI group were comparable to those in the non-RI group. The RI group achieved a response as rapid and deep as the non-RI group. Long-term efficacy in the RI group were not inferior (as shown in Figure1) as non-PI group. In terms of safety, both group developed cytokine release syndrome (CRS) Only one case of grade 2 immune effector cell-associated neurotoxicity syndrome (ICANS) was reported in the non-RI group, while no cases of ICANS occurred in the RI group. A slightly higher prevalence of short-term severe cytopenia was noted in the RI group, but recovered by day 60.

Conclusions: In the FUMANBA-1 study, R/RMM patients with RI could achieved a similarly rapid, deep, and durable response with Eque-cel treatment without compromising safety status. Additionally, renal function was improveddue to the clearance of myeloma cells by Eque-cel.

The principal investigator of this study, Professor Lugui Qiu, from the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, and Professor Chunrui Li, from Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, stated: "In the past, we were concerned about the potential intolerance of R/R MM patients with impaired renal function to CAR-T treatment. The current study confirmed that even in patients with renal impairment, Eque-cel can induce rapid, deep, and durable remission, with efficacy comparable to that of patients without renal impairment. This data provides invaluable insights for clinical treatment with Eque-cel for camplcated case.

Dr. Yongke Zhang, Chief Scientific Officer of IASO Bio, said: "We are pleased to present the retrospective study on the use of Eque-cel (Fucaso^TM) for treating R/RMM patients with renal impairment at the IMS Annual Meeting. Data from the FUMANBA-1 study demonstrated the promising efficacy and safety of Eque-cel in this patient population, with the added benefit of improving renal function. We believe CAR-T therapy will offer new therapeutic options for R/RMM patients with moderate to severe renal function impairment, enabling broader application in the field of myeloma treatment."

About FUMANBA-1 Study

The FUMANBA-1 Study is a Phase Ib/II, single-arm, multicenter study to assess the efficacy and safety of the investigational drug Equecabtagene Autoleucel, a fully human BCMA CAR-T cell therapy, in patients with R/R MM who have received 3 or more lines of treatment.

About IASO Bio

IASO Bio is a biopharmaceutical company focused on the discovery and development of novel cell therapies and biologics for oncology and autoimmune diseases. IASO Bio possesses comprehensive capabilities spanning the entire drug development process, from early discovery to clinical development, regulatory approval, and commercialization.

Its pipeline includes a diversified portfolio of over 10 novel products, including Equecabtagene Autoleucel (a fully human BCMA CAR-T injection). Equecabtagene Autoleucel received Biologics License Application (BLA) approval from China's National Medical Products Administration (NMPA) in June 2023 and U.S. FDA IND approval for the treatment of R/RMM in December 2022.

Leveraging its strong management team, innovative product pipeline, as well as integrated and high quality manufactural and clinical capabilities, IASO aims to deliver transformative, curable, and affordable therapies that fulfil unmet medical needs to patients in China and around the world. For more information, please visit http://www.iasobio.com or www.linkedin.com/company/iasobiotherapeutics. 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

IASO Bio Presented the Outcomes of Relapsed/Refractory Multiple Myeloma (R/RMM) Patients with Renal Impairment Treated with Equecabtagene Autoleucel (Fucaso™) at 2024 IMS Annual Meeting

IASO Bio Presented the Outcomes of Relapsed/Refractory Multiple Myeloma (R/RMM) Patients with Renal Impairment Treated with Equecabtagene Autoleucel (Fucaso™) at 2024 IMS Annual Meeting

IASO Bio Presented the Outcomes of Relapsed/Refractory Multiple Myeloma (R/RMM) Patients with Renal Impairment Treated with Equecabtagene Autoleucel (Fucaso™) at 2024 IMS Annual Meeting

KAZAN, Russia, Sept. 28, 2024 /PRNewswire/ -- The "BRICS Dialogue on Civilizations" event took place in Kazan, Russia, on September 24^th, with over 300 participants, including representatives from institutions, experts, scholars, and youth from BRICS countries.

The event, themed "Gathering the Power of People-to-people and Cultural Exchanges to Build a Bright Future for BRICS", was co-hosted by the State Council Information Office of China, the Government of the Republic of Tatarstan of Russia, and the Consulate-General of China in Kazan. The event was jointly organized by the China Intercontinental Communication Center and Kazan Federal University.

Organizers emphasized that exchanges and mutual learning among civilizations are crucial drivers of human progress and world peace. They believe that through this dialogue, BRICS contriess can deepen mutual understanding and traditional friendships, strengthen cultural ties, and inspire more BRICS citizens to become ambassadors for cultural dialogue. They hope BRICS countries will actively support the Global Civilization Initiative, focus on people-to-people connections, and use the "BRICS+" cooperation platform to deepen cultural exchanges and foster new chapters of mutual understanding and friendship. Together, they aim to contribute "BRICS strength" to building a community with a shared future for humanity.

In her remarks, Leyla Rinatovna Fazleeva highlighted that under the BRICS cooperation mechanism, cultural exchange and cooperation between BRICS nations have steadily deepened. She encouraged the expanded BRICS nations to continue fostering cultural dialogue, enriching exchange content, and building cooperative networks to turn the vision of cultural exchanges into reality.

During the story-sharing session, participants shared inspiring stories of how BRICS nations have fostered mutual understanding and deepened friendships through cross-border and cross-generational dialogues, advancing together through practical cooperation.

Tia Ju, Vice President of the Legislative Assembly of the State of Rio de Janeiro in Brazil, gave a speech via video link, and Talita Bernardo, Head of the office of the Second Vice President of the Legislative Assembly of the State of Rio de Janeiro, shared the deep ties that have formed between Rio de Janeiro and the Chinese people since the first Chinese immigrants arrived over 200 years ago.

Tamara Moskvina, the 83-year-old honored Russian coach, Denis Petrov, silver medalist at the Albertville Winter Olympics, Chen Lu, China's first world figure skating champion, and Anna Shcherbakova, Beijing Winter Olympics women's figure skating single champion, shared heartwarming stories of the friendship passed down throngh three generations of figure skaters from China and Russia.

Prof B.R.Deepak, Director of the Centre for Chinese and Southeast Asian Studies at Jawaharlal Nehru University, reflected on the long history of friendly exchanges between China and India, recalling Tagore's visit to China a century ago.

South African scholar Professor Paul Zilungisele Tembe used the song Glorious Years to highlight the BRICS countries' shared commitment to openness, inclusivity, and their common desire for global peace and development.

The BRICS Through the Lens photo exhibition attracted visitors, showcasing captivating moments from BRICS nations across areas such as economy, society, history, culture, environment, and youth development. Photographers from the UAE and Ethiopia captured the vibrancy of cities and the rhythm of rapidly changing times, while those from Egypt and Iran focused on colorful festival scenes, weaving a rich tapestry of cultural diversity. The China Horse Industry Association contributed stunning works that depicted the harmonious coexistence between humans and nature, while young people from Russia, Saudi Arabia, and other countries embodied the energy and hope for the future.

At the event, performers from the China Orient Ochestra played a medley of BRICS countries' famous songs using traditional Chinese instruments guzheng, showcasing the diverse cultural charm of BRICS countries and receiving enthusiastic applause from the audience.

The Kazan Chamber Orchestra of Russia delivered melodies rich in Tatar characteristics and played Glorious Years, which brought the event to its climax.

Zhan Changgan, a member of the China Arts and Crafts Association and a director of the Jiangxi Arts and Crafts Association, demonstrated the art of Jingdezhen ceramics to international guests. He also created ceramic works themed around the national flowers of BRICS countries, depicting a vivid scene of unity and collaboration among the BRICS nations.

At the event, Zhejiang University presented A Comprehensive Collection of Ancient Chinese Paintings to Kazan Federal University. The special exhibition of this collection drew considerable interest from the attendees.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

"BRICS Dialogue on Civilizations" event Successfully Held in Kazan

"BRICS Dialogue on Civilizations" event Successfully Held in Kazan

"BRICS Dialogue on Civilizations" event Successfully Held in Kazan

"BRICS Dialogue on Civilizations" event Successfully Held in Kazan